PAC 14028

Drug Profile

PAC 14028

Alternative Names: PAC 14028

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Amorepacific
  • Class Anti-inflammatories; Skin disorder therapies
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Pruritus; Rosacea; Seborrhoeic dermatitis
  • Discontinued Skin disorders

Most Recent Events

  • 10 Jan 2017 Chemical structure information added
  • 10 Jan 2017 Discontinued - Phase-I for Skin disorders (In volunteers) in South Korea (PO)
  • 10 Nov 2016 Phase-III clinical trials in Atopic dermatitis (In adults, In adolescents) in South Korea (Topical) (NCT02965118)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top